@article{f0a8cb996add4298b2204e1d63caa114,
title = "Estimating the attributable fraction of mortality from acute respiratory distress syndrome to inform enrichment in future randomised clinical trials",
abstract = "Background Efficiency of randomised clinical trials of acute respiratory distress syndrome (ARDS) depends on the fraction of deaths attributable to ARDS (AF ARDS) to which interventions are targeted. Estimates of AF ARDS in subpopulations of ARDS could improve design of ARDS trials. Methods We performed a matched case-control study using the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE cohort. Primary outcome was intensive care unit mortality. We used nearest neighbour propensity score matching without replacement to match ARDS to non-ARDS populations. We derived two separate AF ARDS estimates by matching patients with ARDS to patients with non-acute hypoxaemic respiratory failure (non-AHRF) and to patients with AHRF with unilateral infiltrates only (AHRF-UL). We also estimated AF ARDS in subgroups based on severity of hypoxaemia, number of lung quadrants involved and hyperinflammatory versus hypoinflammatory phenotypes. Additionally, we derived AF AHRF estimates by matching patients with AHRF to non-AHRF controls, and AF AHRF-UL estimates by matching patients with AHRF-UL to non-AHRF controls. Results Estimated AF ARDS was 20.9% (95% CI 10.5% to 31.4%) when compared with AHRF-UL controls and 38.0% (95% CI 34.4% to 41.6%) compared with non-AHRF controls. Within subgroups, estimates for AF ARDS compared with AHRF-UL controls were highest in patients with severe hypoxaemia (41.1% (95% CI 25.2% to 57.1%)), in those with four quadrant involvement on chest radiography (28.9% (95% CI 13.4% to 44.3%)) and in the hyperinflammatory subphenotype (26.8% (95% CI 6.9% to 46.7%)). Estimated AF AHRF was 33.8% (95% CI 30.5% to 37.1%) compared with non-AHRF controls. Estimated AF AHRF-UL was 21.3% (95% CI 312.8% to 29.7%) compared with non-AHRF controls. Conclusions Overall AF ARDS mean values were between 20.9% and 38.0%, with higher AF ARDS seen with severe hypoxaemia, four quadrant involvement on chest radiography and hyperinflammatory ARDS.",
keywords = "ARDS, clinical epidemiology",
author = "Rohit Saha and T{\`a}i Pham and Pratik Sinha and Maddali, {Manoj V.} and Giacomo Bellani and Eddy Fan and Charlotte Summers and Abdel Douiri and Rubenfeld, {Gordon D.} and Calfee, {Carolyn S.} and Laffey, {John Gerard} and McAuley, {Daniel Francis} and Manu Shankar-Hari",
note = "Funding Information: The LUNG-SAFE study was funded and supported by the European Society of Intensive Care Medicine (ESICM), Brussels, Belgium, by St Michael{\textquoteright}s Hospital, Toronto, Canada, and by the University of Milan-Bicocca, Monza, Italy. ESICM provided support in data collection and study coordination. ESICM, St Michael{\textquoteright}s Hospital, Toronto and University of Milan-Bicocca had no role in the design and conduct of the study; management, analysis and interpretation of the data; preparation, review or approval of the manuscript or decision to submit the current manuscript for publication. Funding Information: CS is funded by UKRI (MR/S035753/1 and MR/X005070/1) and the National Institute for Health and Care Research (NIHR133788). Work in her research group is supported by GlaxoSmithKline, the Wellcome Trust and the Cambridge NIHR Biomedical Research Centre, and she has received consultancy fees from AbbVie, Sanofi and GlaxoSmithKline. CSC is funded by National Institutes of Health R35-HL140026 and reports grant funding from Roche-Genentech and Quantum Leap Healthcare collaborative, in addition to the National Institutes of Health, and consulting fees from Vasomune, Gen1e Life Sciences, Cellenkos and Janssen. EF reports personal fees from ALung Technologies, Aerogen, Baxter, GE Healthcare, Inspira and Vasomune outside the submitted work. JGL is funded by a Future Research Leaders Award (16-FRL-3845) from Science Foundation Ireland and reports receiving consulting fees from Baxter and from GlaxoSmithKline. RS reports no conflicts. MS-H is funded by a clinician scientist fellowship from the National Institute for Health Research (CS-2016-16-011) and reports receiving grants from the NIHR, MRC, EME, HTA, Huo Foundation and highlights industry support for TRAITS research programme (a Chief Scientists Office, Scotland funded time critical precision medicine in adult critically ill patients (TRAITS Programme)). Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2023",
month = oct,
day = "1",
doi = "10.1136/thorax-2023-220262",
language = "English",
volume = "78",
pages = "990--1003",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",
number = "10",
}